Review of publications of HSCT and SOT for any indications
| Reference . | N . | Age, y . | Transplanted SO . | Primary disease (n) . | Indication for secondary transplantation (n) . | Time between SOT and BMT . |
|---|---|---|---|---|---|---|
| SOT after BMT | ||||||
| 94 | 13 | 4.5-50 | Kidney | AML (5), CML (3), ALL (2), WAS (1), SAA (1), FA (1) | BMT nephropathy (4), RF (4), membranous nephritis (1), MPGN (1), radiation nephritis (1), HUS (2) | 1-10 y |
| 14 | 4-47 | Liver | AML (4), CML (3), ALL (3), MDS (2), NHL (1), SD/SAA (1) | VOD (9), GVHD (4), GVHD cirrhosis (1) | 0.06-3 y | |
| 9 | 3-37 | Lung | AML (1), CML (1), ALL (4), WAS (1), SAA (1), ID (1) | GVHD (6), lung fibrosis (1), restrictive lung disease (1), radiation pneumonitis (1) | 1.3-14 y | |
| 1 | 26 | Heart | AML | Cardiomyopathy | 1 y | |
| BMT for malignancy after SOT | ||||||
| 94 | 7 | 0.3-45 | Liver | Hepatitis (5), ALF (1), hepatitis B and lymphoma (1) | SAA (5), recurrent lymphoma (1), HLH (1) | 0.17-3.7 y |
| 4 | 30-42 | Kidney | Focal GS (2), chronic GN (1), progressive GN (1) | AML (1), AML relapse (1), lymphoma (1), prolymphocytic leukemia (1) | 7.5-10 y | |
| 1 | 23 | Heart | Viral cardiomyopathy | MDS | 10 y | |
| Combined BMT and SOT | ||||||
| 95 | 1 | 43 | Liver | Breast cancer liver metastasis | 85 d | |
| 50 | 1 | 18 | Liver | Hyper-IgM syndrome and cholangiopathy | 34 d | |
| 96 | 7 | 34-55 | Kidney | MM and ESRD | Same day | |
| 51 | 10 | 22-46 | Kidney | Alport (4), PKD (2), MPGN (2), reflux uropathy (1), focal GS (1) | Same day | |
| 52 | 19 | 18-64 | Kidney | Alport (1), PKD (4), IgA (3), DM (2), MPGN (1), HTN (3), membranous (1), chronic GN (1), urinary reflux (2), unknown (1) | 1 d | |
| 53 | 38 | 21-62 | Kidney | Alport (1), PKD (4), IgA (10), SLE (4), DM (2), GN (2), FSGS (1), dysplasia (1), urinary reflux (1), CIN (1), obstruction (1), unknown (10) | Same day | |
| 54 | 4 | 38-67 | Kidney | MM and ESRD (3), HD and ESRD (1) | Same day | |
| 97 | 1 | 30 | Kidney | MM and ESRD |
| Reference . | N . | Age, y . | Transplanted SO . | Primary disease (n) . | Indication for secondary transplantation (n) . | Time between SOT and BMT . |
|---|---|---|---|---|---|---|
| SOT after BMT | ||||||
| 94 | 13 | 4.5-50 | Kidney | AML (5), CML (3), ALL (2), WAS (1), SAA (1), FA (1) | BMT nephropathy (4), RF (4), membranous nephritis (1), MPGN (1), radiation nephritis (1), HUS (2) | 1-10 y |
| 14 | 4-47 | Liver | AML (4), CML (3), ALL (3), MDS (2), NHL (1), SD/SAA (1) | VOD (9), GVHD (4), GVHD cirrhosis (1) | 0.06-3 y | |
| 9 | 3-37 | Lung | AML (1), CML (1), ALL (4), WAS (1), SAA (1), ID (1) | GVHD (6), lung fibrosis (1), restrictive lung disease (1), radiation pneumonitis (1) | 1.3-14 y | |
| 1 | 26 | Heart | AML | Cardiomyopathy | 1 y | |
| BMT for malignancy after SOT | ||||||
| 94 | 7 | 0.3-45 | Liver | Hepatitis (5), ALF (1), hepatitis B and lymphoma (1) | SAA (5), recurrent lymphoma (1), HLH (1) | 0.17-3.7 y |
| 4 | 30-42 | Kidney | Focal GS (2), chronic GN (1), progressive GN (1) | AML (1), AML relapse (1), lymphoma (1), prolymphocytic leukemia (1) | 7.5-10 y | |
| 1 | 23 | Heart | Viral cardiomyopathy | MDS | 10 y | |
| Combined BMT and SOT | ||||||
| 95 | 1 | 43 | Liver | Breast cancer liver metastasis | 85 d | |
| 50 | 1 | 18 | Liver | Hyper-IgM syndrome and cholangiopathy | 34 d | |
| 96 | 7 | 34-55 | Kidney | MM and ESRD | Same day | |
| 51 | 10 | 22-46 | Kidney | Alport (4), PKD (2), MPGN (2), reflux uropathy (1), focal GS (1) | Same day | |
| 52 | 19 | 18-64 | Kidney | Alport (1), PKD (4), IgA (3), DM (2), MPGN (1), HTN (3), membranous (1), chronic GN (1), urinary reflux (2), unknown (1) | 1 d | |
| 53 | 38 | 21-62 | Kidney | Alport (1), PKD (4), IgA (10), SLE (4), DM (2), GN (2), FSGS (1), dysplasia (1), urinary reflux (1), CIN (1), obstruction (1), unknown (10) | Same day | |
| 54 | 4 | 38-67 | Kidney | MM and ESRD (3), HD and ESRD (1) | Same day | |
| 97 | 1 | 30 | Kidney | MM and ESRD |
ALF, acute liver failure; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BMT, bone marrow transplantation; CIN, chronic interstitial nephritis; CML, chronic myeloid leukemia; DM, diabetes mellitus; ESRD, end-stage renal disease; FA, Fanconi anemia; FSGS, focal segmental glomerulosclerosis; GN, glomerulonephritis; GS, glomerulosclerosis; HD, Hodgkin disease; HLH, hemophagocytic lymphohistiocytosis; HTN, hypertension; HUS, hemolytic uremic syndrome; ID, immune deficiency; Ig, immunoglobulin; MDS, myelodysplasia; MM, multiple myeloma; MPGN, membranous proliferative glomerulonephritis; NHL, non-Hodgkin lymphoma; PKD, polycystic kidney disease; RF, renal failure; SAA, severe aplastic anemia; SD, Shwachman-Diamond syndrome; VOD, veno-occlusive disease; WAS, Wiskott-Aldrich syndrome.